ONO 1301
Modify Date: 2024-01-02 11:34:18
ONO 1301 structure
|
Common Name | ONO 1301 | ||
|---|---|---|---|---|
| CAS Number | 176391-41-6 | Molecular Weight | 428.48000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H24N2O4 | Melting Point | 147-158 °C | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of ONO 1301ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3]. |
| Name | ono-1301 |
|---|---|
| Synonym | More Synonyms |
| Description | ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | ONO 1301 (ONO-AP 500-02) inhibits collagen-induced aggregation in a concentration-dependent manner, with an IC50 value of 460 nM[3]. ONO-1301 (0-1000 nM) significantly increases alkaline phosphatase (ALP) activity in the primary osteoblasts and ST2 cells[3]. |
| In Vivo | ONO-1301 (6 mg/kg; p.o.; /daily for 4 weeks) improves the hemodynamic status of rats with dilated cardiomyopathy after experimental autoimmune myocarditis[1]. Animal Model: Eight-week-old male Lewis rats (rat model of myosin-induced experimental autoimmune myocarditis)[1] Dosage: 6 mg/kg Administration: Orally; /daily for 4 weeks Result: Hemodynamic parameters and plasma brain natriuretic peptide (BNP) level were significantly improved. |
| References |
| Melting Point | 147-158 °C |
|---|---|
| Molecular Formula | C26H24N2O4 |
| Molecular Weight | 428.48000 |
| Exact Mass | 428.17400 |
| PSA | 81.01000 |
| LogP | 4.73390 |
| Storage condition | -20° C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
|
Inhibition of cyclooxygenase-2 causes a decrease in coronary flow in diabetic mice. The possible role of PGE2 and dysfunctional vasodilation mediated by prostacyclin receptor.
J. Physiol. Biochem. 71 , 351-8, (2015) Several lines of evidence suggest that cyclooxygenase-2 (COX-2) activity can have a beneficial role in the maintenance of vascular tone of the blood vessels in diabetes. Specifically, the increased pr... |
|
|
Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage.
Clin. Exp. Med. 15 , 245-53, (2015) Chemokines play essential roles during inflammatory responses and in pathogenesis of inflammatory diseases. Monocyte chemotactic protein-1 (MCP-1) is a critical chemokine in the development of atheros... |
|
|
ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells.
Acta Med. Okayama 69(1) , 1-15, (2015) Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel thera... |
| 2-((5-(2-(((phenyl(pyridin-3-yl)methylene)amino)oxy)ethyl)-7,8-dihydronaphthalen-1-yl)oxy)acetic acid |
| Acetic acid, ((7,8-dihydro-6-methyl-5-(2-(((phenyl-3-pyridinylmethylene)amino)oxy)ethyl)-1-naphthalenyl)oxy)- |
| 7,8-Dihydro-5-[(E/Z)-[[α-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid |